Rocket Pharmaceuticals Form 144: Insiders to Sell 12,109 Shares

Rhea-AI Filing Summary

Rocket Pharmaceuticals, Inc. (RCKT) Form 144 notifies a proposed sale of 12,109 common shares (aggregate market value $36,553.44) to be sold on or about 08/14/2025 on NASDAQ. The shares were acquired by vesting of restricted stock from the issuer on 08/12/2025 and were paid as compensation. The filing also discloses two recent sales by Martin Wilson of 946 and 587 shares on 05/16/2025 and 05/20/2025, generating gross proceeds of $6,175.02 and $3,783.80 respectively. The document shows the total shares outstanding as 107,903,871. Several standard filer contact and signature fields appear blank in the provided content.

Insights

Securities Analyst

TL;DR: Routine insider sale notice showing vested compensation shares to be sold; disclosure is standard and likely low market impact.

The Form 144 documents a proposed sale of 12,109 common shares received via restricted stock vesting and designated as compensation. The aggregate market value reported is $36,553.44 with an intended sale date of 08/14/2025 on NASDAQ. Two small prior sales by Martin Wilson earlier in May 2025 are disclosed with modest proceeds. This filing appears to be a routine compliance notice rather than a material corporate event. The filing as provided omits several filer contact and signature details, which prevents verification of some administrative elements.

Corporate Governance Expert

TL;DR: The transaction reflects executive/employee compensation vesting and standard resale reporting; governance concerns are minimal but documentation is incomplete.

The securities were acquired through restricted stock vesting from the issuer on 08/12/2025 and are to be sold by the person for whose account they vested. The filing includes required historical sales by the same person in May 2025. From a governance perspective, vesting-to-sale transactions are common and permissible when reported on Form 144. However, the provided content omits explicit filer identification and signature/date details, which are important for complete disclosure and should be present in the official filing record.

FAQ

What does the Form 144 filed for RCKT report?

The Form 144 reports a proposed sale of 12,109 common shares (aggregate market value $36,553.44) to be sold on or about 08/14/2025 on NASDAQ.

How were the 12,109 RCKT shares acquired?

The shares were acquired on 08/12/2025 through restricted stock vesting from the issuer and the payment is recorded as compensation.

Were there any recent sales by the same person in the last three months?

Yes. Martin Wilson sold 946 shares on 05/16/2025 for $6,175.02 and 587 shares on 05/20/2025 for $3,783.80.

How many shares does Rocket Pharmaceuticals report outstanding in this filing extract?

The filing shows 107,903,871 shares outstanding.

Does the provided content include the filer’s contact and signature information?

No. The supplied extract shows blank or missing filer contact fields and does not include an explicit signature or date in the visible text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 05:47 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001704342
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROCKET PHARMACEUTICALS, INC.
SEC File Number	001-36829
Address of Issuer	350 FIFTH AVENUE SUITE 7530 NEW YORK NEW YORK 10118
Phone	646-440-9100
Name of Person for Whose Account the Securities are To Be Sold	Wilson Martin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	12109	36553.44	107903871	08/14/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/12/2025	Restricted Stock Vesting	Issuer			12109	08/12/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martin Wilson 9 Cedarbrook Drive Cranbury NJ 08512	Common	05/16/2025	946	6175.02
Martin Wilson 9 Cedarbrook Drive Cranbury NJ 08512	Common	05/20/2025	587	3783.80

144: Remarks and Signature

Remarks
Date of Notice	08/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Bradley Camilo, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Martin Wilson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)